Omalizumab treatment in brittle asthma

Asthma is a heterogeneous disease with variable characteristics such as lung function, symptoms and control, body weight, pattern of inflammation, and response to treatment. Brittle asthma is one of clinical phenotypes of asthma with unclear pathogenic mechanisms and appropriate treatment. Analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Skiepko, Roman, Zietkowski, Ziemowit, Skiepko, Urszula, Budny, Wojciech, Lukaszyk, Mateusz, Bodzenta-Lukaszyk, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952054/
https://www.ncbi.nlm.nih.gov/pubmed/24683396
http://dx.doi.org/10.5114/pdia.2014.40658
_version_ 1782307157253816320
author Skiepko, Roman
Zietkowski, Ziemowit
Skiepko, Urszula
Budny, Wojciech
Lukaszyk, Mateusz
Bodzenta-Lukaszyk, Anna
author_facet Skiepko, Roman
Zietkowski, Ziemowit
Skiepko, Urszula
Budny, Wojciech
Lukaszyk, Mateusz
Bodzenta-Lukaszyk, Anna
author_sort Skiepko, Roman
collection PubMed
description Asthma is a heterogeneous disease with variable characteristics such as lung function, symptoms and control, body weight, pattern of inflammation, and response to treatment. Brittle asthma is one of clinical phenotypes of asthma with unclear pathogenic mechanisms and appropriate treatment. Analysis of 2 described cases suggests that omalizumab could be useful in the treatment of brittle allergic asthma.
format Online
Article
Text
id pubmed-3952054
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-39520542014-03-28 Omalizumab treatment in brittle asthma Skiepko, Roman Zietkowski, Ziemowit Skiepko, Urszula Budny, Wojciech Lukaszyk, Mateusz Bodzenta-Lukaszyk, Anna Postepy Dermatol Alergol Case Report Asthma is a heterogeneous disease with variable characteristics such as lung function, symptoms and control, body weight, pattern of inflammation, and response to treatment. Brittle asthma is one of clinical phenotypes of asthma with unclear pathogenic mechanisms and appropriate treatment. Analysis of 2 described cases suggests that omalizumab could be useful in the treatment of brittle allergic asthma. Termedia Publishing House 2014-02-25 2014-02 /pmc/articles/PMC3952054/ /pubmed/24683396 http://dx.doi.org/10.5114/pdia.2014.40658 Text en Copyright © 2014 Termedia http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Skiepko, Roman
Zietkowski, Ziemowit
Skiepko, Urszula
Budny, Wojciech
Lukaszyk, Mateusz
Bodzenta-Lukaszyk, Anna
Omalizumab treatment in brittle asthma
title Omalizumab treatment in brittle asthma
title_full Omalizumab treatment in brittle asthma
title_fullStr Omalizumab treatment in brittle asthma
title_full_unstemmed Omalizumab treatment in brittle asthma
title_short Omalizumab treatment in brittle asthma
title_sort omalizumab treatment in brittle asthma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952054/
https://www.ncbi.nlm.nih.gov/pubmed/24683396
http://dx.doi.org/10.5114/pdia.2014.40658
work_keys_str_mv AT skiepkoroman omalizumabtreatmentinbrittleasthma
AT zietkowskiziemowit omalizumabtreatmentinbrittleasthma
AT skiepkourszula omalizumabtreatmentinbrittleasthma
AT budnywojciech omalizumabtreatmentinbrittleasthma
AT lukaszykmateusz omalizumabtreatmentinbrittleasthma
AT bodzentalukaszykanna omalizumabtreatmentinbrittleasthma

Ejemplares similares